no mention of Er+ Her2- #mbc in @TeamImugene CEO Chong’s presentation at Morgan Healthcare Conference.
I’m pretty sure they have Er+ #mbc patients in the ongoing cf-33 trial (oncarlytic virus). I assume Er+ will be in the upcoming OnCARlytics trial (cf-33 w/ cd19).
Anyone know for sure (not guessing)? Will we have to wait another year to hear?
only #TNBC was mentioned on the presentation slide 🤨
@rushmorealum@TeamImugene To really pin point it- would be nice to know if there are Er+ mbc patients in the latest and highest cohort.
It doesnt help if there were er+ folks in lower cohorts but they left or aren’t included at the present time. thanks
@BhaiyaJiSmiless@MargettsRenee@rushmorealum i hear you. the highs and lows of hoping for something is not only exhausting but mind numbing. praying for something of value in 24.
Is venture philanthropy still a thing?
@RNAoncology has something novel for breast cancer.
TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer- regardless of type.
This could really help a lot of women with breast cancer.
They’ll be at JP Morgan health care conference in the next couple of days.
Company is a bunch of doctors and needs an infusion after promising Phase O presented at San Antonio.
Please take a look
https://t.co/anDwDaqF0d
@melindagates@JohnKuelper@mackenziescott@ChanZuckerberg@parkerici@CancerResrch@ScottGottliebMD@fastercures@KathyGiusti@kschnee66@FDACDERDirector @NIHDirector
Is venture philanthropy still a thing?
@RNAoncology has something novel for breast cancer.
TransCode’s lead therapeutic candidate, TTX-MC138, is a targeted therapy designed to treat cancer patients with metastatic cancer- regardless of type.
This could really help a lot of women with breast cancer.
They’ll be at JP Morgan health care conference in the next couple of days.
Company is a bunch of doctors and needs an infusion after promising Phase O presented at San Antonio.
Please take a look
https://t.co/anDwDaqF0d
@melindagates@JohnKuelper@mackenziescott@ChanZuckerberg@parkerici@CancerResrch@ScottGottliebMD@fastercures@KathyGiusti@kschnee66@FDACDERDirector @NIHDirector
@BhaiyaJiSmiless@MargettsRenee@rushmorealum where does this thought (without evidence either way ) get us as patients? i guess i’ll just be depressed and hope it shows some value as it’s only in the third cohort of phase 1.
@hoffmann6383 as always ty for the reply and for staying on top of the ever changing nwbo landscape. i’m a bit of an outsider but have come to believe the dcvax poly combo for solid tumors is a game changer #nwbo#mbc
@elonmusk i’m dying. of breast cancer. would you mind giving a fat boost to @RNAoncology for their mRNA treatment?
They are brilliant doctors but stink at financials. they have a great drug candidate TTX-MC138.
https://t.co/rr6efX8Hpf
has a human ever admitted trying Erso DFP ? the latest version?
How could it be worse than the red devil?
I’ll never make it 5 years. what is going on each day at Oncoteq? Cant there be right to try? please. i don’t want to die
@ErSOActivism@PartexNV
It's a Christmas miracle! $NWBO submitted a marketing application for the DCVax brain tumor therapy to the UK regulators.
We can now start the clock on its rejection.